Acta Scientific Microbiology (ISSN: 2581-3226)

Research Article Volume 6 Issue 6

Molecular Docking - Study of Potential Cyclophilin-Dependent Mechanism of SARS-CoV-2 Viral Entry

Aneta Maria Molenda*

Department of Molecular Genetics, UK

*Corresponding Author: Aneta Maria Molenda, Department of Molecular Genetics, UK.

Received: April 27, 2023; Published: May 30, 2023


Objectives: The aim of this article is to analyse interaction of the SARS-CoV2 fragments with cyclophilins and to validate the mechanism of the viral entry involving spike glycoprotein or membrane proteins.

Coronavirus Disease: COVID-19 is a disease caused by RNA virus that got potential to cause respiratory and intestinal illness in humans as well as animals. There are 7 different type of Coronavirus diseases (229E, NL63, OC43, HKU1, MERS-CoV, SARS-CoV, SARS-CoV-2) reported in humans that are known to cause illness ranging from common cold to more severe forms [1]. The epicentre of the COVID-19 disease was Wuhan city, Huban province of China where a cluster of unexplained pneumonia cases of unknown aetiology were officially reported on Dec 31 2019 [2]. Though Covid-19 has a lower mortality rate (2.3%) than SARS (9.5%) or MERS (34.4%) it is highly transmissible and has rapidly progressed from epidemic to pandemic scale [3].

 Keywords: SARS-CoV-2; Covid-19; Docking


    1. “Centers for Disease Control and Prevention”. Coronavirus (2020).
    2. World Health Organisation. “Pneumonia of unknown cause - China” (2020).
    3. Petrosillo., et al. “COVID-19, SARS and MERS: are they closely related?” Clinical Microbiology and Infection 26.6 (2020): 729-734.
    4. Li., et al. “Structure, function, and evolution of coronavirus spike proteins”. Annual Review of Virology 3 (2016): 237-261.
    5. Almehdi., et al. “SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies”. Infection 49.5 (2021): 855-876. 
    6. Fani M., et al. “Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections”. Future Medicine Ltd Future Virology 15.5 (2020): 317-323.
    7. Huang., et al. “Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19”. Acta Pharmacologica Sinica 41 (2020): 1141-1149.
    8. Bianchi., et al. “Sars-CoV-2 Envelope and Membrane Proteins: Structural Differences Linked to Virus Characteristics?” Hindawi BioMed Research International (2020): 6.
    9. Mahtarin., et al. “Structure and dynamics of membrane protein in SARS-CoV-2”. Journal of Biomolecular Structure and Dynamics (2020): 4725-4738.
    10. Neuman BW., et al. “A structural analysis of M protein in coronavirus assembly and morphology”. The Journal of Structural Biology 174 (2011): 11-22.
    11. Radzikowska., et al. “Distribution of ACE2, CD147, CD26, and other SARS‐CoV‐2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID‐19 risk factors”. Allergy 75.11 (2020): 2829-2845.
    12. Gur., et al. “Conformational transition of SARS-CoV-2 spike glycoprotein between its closed and open states”. The Journal of Chemical Physics 153.7 (2020): 075101.
    13. Lan., et al. “Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor”. Nature 581.7807 (2020): 215-220.
    14. Kumari., et al. “Cyclophilins Proteins in search of function”. Plant Signaling and Behavior 8.1 (2013): e22734.
    15. Qu., et al. “The Roles of CD147 and/or Cyclophilin A in Kidney Diseases Review Article”. Hindawi Publishing Corporation Mediators of Inflammation (2014): 10.
    16. Chen., et al. “Function of HAb18G/CD147 in Invasion of Host Cells by Severe Acute Respiratory Syndrome Coronavirus”. The Journal of Infectious Diseases 191.5 (2005): 755-760.
    17. Parkinson., et al. “Dynamic data-driven meta-analysis for prioritisation of host genes implicated in COVID-19”. Scientific Report 10.1 (2020): 22303.
    18. Allain., et al. “Cyclophilin B Binding to Platelets Supports Calcium-Dependent Adhesion to Collagen”. Blood 94.3 (1999): 976-983.
    19. Allain., et al. “Interaction with glycosaminoglycans is required for cyclophilin B to trigger integrin-mediated adhesion of peripheral blood T lymphocytes to extracellular matrix”. Proceedings of the National Academy of Sciences (PNAS) of the United States of America 99.5 (2002): 2714-2719.
    20. Bukrinsky., et al. “Extracellular cyclophilins in health and disease”. Biochimica et Biophysica Acta General Subjects 1850.10 (2015): 2087-2095. 
    21. Hopkins., et al. “The role of immunophilins in viral infection”. Biochimica et Biophysica Acta General Subjects 1850.10 (2015): 2103-2110.
    22. Dawar., et al. “Cyclophilin A: A Key Factor in Virus Replication and Potential Target for Anti-viral Therapy”. Current Issues in Molecular Biology 21 (2017): 1-20.
    23. Wilde., et al. “Cyclophilins and cyclophilin inhibitors in nidovirus replication”. Virology 522 (2018): 46-55.
    24. Jean-Michel Pawlotsky. “COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir”. Clinical Infectious Diseases® 71.16 (2020): 2191-2194.
    25. Ma., et al. “NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon”. Antimicrobial Agents and Chemotherapy 50.9 (2006): 2976-2982.
    26. Pushkarsky., et al. “CD147 facilitates HIV‐1 infection by interacting with virus‐associated cyclophilin A”. Proceedings of the National Academy of Sciences (PNAS) of the United States of America 98 (2001): 6360-6365.
    27. Braaten., et al. “Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells”. The European Molecular Biology Organization (EMBO) Journal 20.6 (2001): 1300-1309.
    28. Watashi., et al. “Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase”. Molecular Cell 19.1 (2005): 111-122.
    29. Elfikya., et al. “Novel guanosine derivatives against MERS CoV polymerase: An in silico perspective”. Journal of Biomolecular Structure and Dynamics (2020): 1-9.
    30. Pfefferle., et al. “The SARS-Coronavirus-Host Interactome: Identification of Cyclophilins as Target for Pan-Coronavirus Inhibitors”. The Public Library of Science (PLOS) Pathogens 7.10 (2011): e1002331.
    31. Sauerhering., et al. “Cyclophilin inhibitors restrict Middle East respiratory syndrome coronavirus via interferon-λ in vitro and in mice”. European Respiratory Journal 56 (2020): 1901826.
    32. Clausen., et al. “SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2”. Cell 183.4 (2020): 1043-1057.e15.
    33. Hao., et al. “Binding of the SARS-CoVCoV-2 Spike Protein to Glycans”. Science Bulletin (Beijing) 66.12 (2021): 1205-1214.
    34. Mycroft-West., et al. “The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding”. Pre-print version posted April 29, (2020).
    35. Helal., et al. “Molecular basis of the potential interaction of SARS-CoV-2 spike protein to CD147 in COVID-19 associated-lymphopenia”. Journal of Biomolecular Structure and Dynamics (2020): 1-11.
    36. Wang., et al. “The cyclophilins”. Genome Biology 6.7 (2005): 226.
    37. Sekhon., et al. “Cyclophilin A-mediated mitigation of coronavirus SARS-CoV-2”. Bioengineering and Translational Medicine 8 (2023): e10436.
    38. Saphire., et al. “Host cyclophilin A mediates HIV-1 attachment to target cells via heparans”. The European Molecular Biology Organization (EMBO) Journal 18.23 (1991): 6771-6785.
    39. Pakula., et al. “Syndecan-1/CD147 association is essential for cyclophilin B-induced activation of p44/42 mitogen-activated protein kinases and promotion of cell adhesion and chemotaxis”. Glycobiology 17.5 (2007): 492-503.
    40. Prakash., et al. “Human Cyclophilin B forms part of a multi-protein complex during erythrocyte invasion by Plasmodium falciparum”. Nature Communications 8 (2017): 1548.
    41. Walls., et al. “Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein”. Cell 180 (2020): 281-292.
    42. Fehr., et al. “Coronaviruses: an overview of their replication and pathogenesis”. Methods in Molecular Biology 1282 (2015): 1-23.
    43. Vajda., et al. “New additions to the ClusPro server motivated by CAPRI”. Proteins: Structure, Function, and Bioinformatics 85.3 (2017): 435-444.  
    44. Kozakov., et al. “The ClusPro web server for protein-protein docking”. Nature Protocols 12.2 (2017): 255-278.
    45. Kozakov., et al. “How good is automated protein docking?” Proteins: Structure, Function, and Bioinformatics 81.12 (2013): 2159-2166.  
    46. Kong., et al. “COVID-19 Docking Server: An interactive server for docking small molecules, peptides and antibodies against potential targets of COVID-19”. Bioinformatics (2020): btaa645. 
    47. Kong., et al. “CoDockPP: a multistage approach for global and site-specific protein-protein docking”. Journal of Chemical Information and Modeling 59.8 (2019): 3556-3564. 
    48. Kong., et al. “Template‐based modeling and ab‐initio docking using CoDock in CAPRI”. Proteins-Structure Function and Bioinformatics 88.8 (2020): 1100-1109.
    49. Trott., et al. “AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading”. The Journal of Computational Chemistry 31 (2010): 455-461. 
    50. Li., et al. “Correcting the impact of docking pose generation error on binding affinity prediction”. BMC Bioinformatics 17 (2016): 308.
    51. Seizer., et al. “Extracellular cyclophilin A activates platelets via EMMPRIN (CD147) and PI3K/Akt signaling, which promotes platelet adhesion and thrombus formation in vitro and in vivo”. Arteriosclerosis, Thrombosis, and Vascular Biology 35 (2015): 655-663.
    52. Cao., et al. “Probing the formation, structure and free energy relationships of M protein dimers of SARS-CoV-2”. Computational and Structural Biotechnology Journal 20 (2022): 573-582.
    53. Neuman., et al. “A structural analysis of M protein in coronavirus assembly and morphology”. The Journal of Structural Biology 174.1 (2011): 11-22.





    Citation: Aneta Maria Molenda. “Molecular Docking - Study of Potential Cyclophilin-Dependent Mechanism of SARS-CoV-2 Viral Entry". Acta Scientific Microbiology 6.6 (2023): 81-101.


    Copyright: © 2023 Aneta Maria Molenda. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate30%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US